NCT06544694View on ClinicalTrials.gov

A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

October 8, 2024

Primary Completion Date

March 21, 2025

Study Completion Date

March 21, 2025

Conditions
Dry Eye Disease
Interventions
DRUG

0.003% AR-15512

Ophthalmic solution administered via topical ocular instillation

OTHER

Artificial Tears

Commercially available, preservative-free lubricant eye drops

Trial Locations (4)

27529

Oculus Research, Garner

28150

CORE, Inc., Shelby

28451

Wilmington Eye, Leland

40206

Butchertown Clinical Trials, Louisville

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT06544694 - A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease | Biotech Hunter | Biotech Hunter